An indication-based understanding of the Neuroendocrine Carcinoma Market provides critical insight into disease-specific treatment demand and clinical priorities. Neuroendocrine carcinomas can arise in various anatomical locations, each presenting unique diagnostic and therapeutic challenges. The market is expected to reach US$ 4.05 billion by 2031, growing at a CAGR of 8.6% from 2025 to 2031,...